Posted by Michael Wonder on 15 Nov 2024
FDA approves revumenib for relapsed or refractory acute leukaemia with a KMT2A translocation
15 November 2024 - Today, the FDA approved revumenib (Revuforj, Syndax Pharmaceuticals), a menin inhibitor, for relapsed or refractory acute leukaemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and paediatric patients 1 year and older.
Efficacy was evaluated in a single-arm cohort of an open-label, multi-centre trial (AUGMENT-101) in 104 adult and paediatric patients (at least 30 days old) with relapsed or refractory acute leukaemia with a KMT2A translocation.
